The viral social media post in question sheds light on Bill Gates' substantial profit from the Covid-19 pandemic. It reveals that Gates acquired 1,038,674 shares of BioNTech, Pfizer's partner for mRNA Covid vaccines, in September 2019, just months before the pandemic was officially declared.
These shares were obtained at a pre-public offering price of $18.10 per share. In a startling turn, Gates sold off his entire stake in November 2021, at an average price of $300 per share, a move that coincided with his statement questioning the efficacy of vaccines in stopping transmission.
Jordan Schachtel corroborated the post's accuracy by referencing SEC filings, which showed that the Gates Foundation significantly reduced its holdings in BioNTech from over a million shares to just 148,674 shares in the third quarter of 2021. This downsizing represented an 86 percent reduction in their shares. Notably, Gates executed this maneuver during BioNTech's most profitable quarter, indicating a well-timed market move on his part.
Furthermore, Dr. Joseph Mercola penned an extensive article in July 2022, outlining how Pfizer also saw substantial gains from the Covid-19 pandemic. The pharmaceutical giant's revenue for 2022 surged to an unprecedented $100 billion, a clear indication of the financial windfall they experienced as a result of the pandemic. This revelation underscores the significant financial interests at play for various entities within the healthcare industry.
In a revealing video, Bill Gates can be seen acknowledging that the administered shots, often referred to as “clot shots,” do not effectively prevent transmission. This statement contradicts his previous claims about the vaccines' efficacy. This admission has raised questions about the level of foreknowledge Gates may have had about the Covid-19 outbreak and the role of vaccines in its containment.
The viral post provides a detailed account of Bill Gates' substantial profits from the Covid-19 pandemic, stemming from his strategic investments in BioNTech. The timely sale of these shares during BioNTech's peak performance further highlights the financial gains made.
Additionally, Pfizer, along with other pharmaceutical companies, also reaped significant benefits from the pandemic, with record-breaking revenues in 2022.
Finally, Gates' candid admission regarding the limitations of the vaccines in preventing transmission raises important questions about his knowledge and involvement in the handling of the pandemic.
